Anal carcinoma – Survival and recurrence in a large cohort of patients treated according to Nordic guidelines

Leon, Otilia; Guren, Marianne G.; Hagberg, Oskar; Glimelius, Bengt; Dahl, Olav; Havsteen, Hanne; Naucler, Gisela; Svensson, C.; Tveit, Kjell Magne; Jakobsen, Anders; Pfeiffer, Per; Wanderås, Eva Hoff; Ekman, Tor; Lindh, Birgitta; Balteskard, Lise; Frykholm, Gunilla; Johnsson, Anders

doi:10.1016/j.radonc.2014.10.002

Cited by 55 publications

(39 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was 7.8% in the large retrospective analysis by Gerard et al in patients without PII [22]. In a Nordic cohort, it was 2.4% after a PII dose of 45-50 Gy [23], and in a series reported by Ortholan et al, the 5-year actuarial inguinal recurrence rate was 2% after a PII dose of 45-50 Gy, while the rates in T3-T4 and T1-T2 tumors without PII were 30% and 12%, respectively [24]. Therefore, PII should be recommended for all disease stages [23,25,26].…”

Section: Discussionmentioning

confidence: 96%

Evaluation of a 36 Gy elective node irradiation dose in anal cancer

Lepinoy

Lescut

Puyraveau

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Evaluation of a 36 Gy elective node irradiation dose in anal cancer

Lepinoy

Lescut

Puyraveau

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

“…There is considerable variation in radiotherapy doses used, from the relatively lower doses in the initial series (Nigro et al , 1983), through 50.4 Gy in ACT2 to 54–64 Gy in the Nordic countries (Leon et al , 2014). Second techniques that aided the early detection of relapse would facilitate prompt salvage surgery with improved outcomes.…”

Section: Translational Questions In Anal Cancermentioning

confidence: 99%

Biomarkers in anal cancer: from biological understanding to stratified treatment

et al. 2016

View full text Add to dashboard Cite

Squamous cell carcinomas of the anus and anal canal represent a model of a cancer and perhaps the first where level 1 evidence supported primary chemoradiotherapy (CRT) in treating locoregional disease with curative intent. The majority of tumours are associated with infection with oncogenic subtypes of human papilloma virus and this plays a significant role in their sensitivity to treatment. However, not all tumours are cured with CRT and there remain opportunities to improve outcomes in terms of oncological control and also reducing late toxicities. Understanding the biology of ASCC promises to allow a more personalised approach to treatment, with the development and validation of a range of biomarkers and associated techniques that are the focus of this review.

show abstract

“…Nevertheless, recent ESTRO guidelines recommend a chemotherapy regimen analogous to the control arm of ACT-II, with 5-FU (1000 mg/m 2 continuous infusion) on days 1-4 and 29-32 with MMC (12 mg/ m 2 bolus) on day 1 [16]. In contrast, another large series described treatment outcomes in 1266 patients treated in Sweden, Norway, and Denmark from 2000 to 2007 according to Nordic guidelines [17]. In this heterogenous group, many patients were treated with cisplatin as opposed to MMC (per the various protocol guidelines), with overall excellent outcomes.…”

Section: Discussionmentioning

confidence: 99%